Retatrutide Research

Is Retatrutide FDA Approved? Regulatory Status Explained

UKPWritten & reviewed by William Heath · Editor, UK Peptides research library2 min readLast reviewed 2026-08-224 cited sources

The short answer

No. Retatrutide is not approved by the FDA, EMA or MHRA and remains investigational everywhere. The position changed in substance during 2026: the pivotal TRIUMPH trials have now read out positively, and Eli Lilly has indicated it intends to file with the FDA in the first quarter of 2027. Filing begins a review; it is not an approval.

Key facts

FDA status
Not approved (investigational)
EMA status
Not approved
MHRA status
Not approved
Trial phase
Phase 3 complete on pivotal trials
TRIUMPH-1 readout
21 May 2026: met primary endpoint
TRIUMPH-2 / -3 readout
July 2026: both met primary endpoints
Stated FDA filing
Q1 2027 (Biologics License Application)

What changed in 2026

Until May 2026 retatrutide was a compound with striking Phase 2 numbers and no pivotal data. That is no longer the case. TRIUMPH-1 reported topline results on 21 May 2026, and TRIUMPH-2 and TRIUMPH-3 followed in July, all meeting their primary endpoints. The regulatory status is unchanged (still not approved), but the reason has changed from "the evidence does not exist yet" to "the evidence exists and has not yet been submitted or reviewed".

Where does it stand in the approval process?

Lilly has stated an intention to submit a Biologics License Application to the FDA in the first quarter of 2027. Submission is the start of a formal review, which commonly runs a year or more, and regulators can request further data or decline. No MHRA or EMA filing timeline has been announced publicly, and a UK authorisation would be a separate decision from any FDA outcome.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

Does the orforglipron approval affect this?

No. The MHRA authorised orforglipron (Foundayo) on 10 August 2026, but marketing authorisations are granted to a specific product for a specific indication. One incretin being licensed carries no implication for the status of a different, investigational compound from the same company.

In the UK retatrutide is supplied for laboratory research only. It is not a licensed medicine, cannot be prescribed or dispensed, and is not for human use outside a registered clinical trial. That position is unaffected by the trial results above.

Frequently asked questions

When will retatrutide be approved?

No approval date exists. The stated plan is an FDA filing in Q1 2027, after which review typically takes a year or more with no guaranteed outcome.

Have the Phase 3 trials finished?

The pivotal trials have reported. TRIUMPH-1 read out in May 2026 and TRIUMPH-2 and -3 in July 2026, with further readouts including maintenance-dosing studies still expected.

Can doctors prescribe it?

No. It has no marketing authorisation in any jurisdiction.

Does a positive Phase 3 mean approval is a formality?

No. Regulators assess the full dossier including manufacturing and long-term safety, and may request additional data.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and reviewed by

William Heath · Editor, UK Peptides research library

William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.

More Retatrutide Research articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.